ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects

Liu, Zhuoyan; Liu, Xuan; Liang, Jiaxin; Liu, Yixin; Hou, Xiaorui; Zhang, Meichuan; Li, Yongyin*; Jiang, Xiaotao*南方医科大学
Frontiers in Immunology2021-10-4DOI: 10.3389/fimmu.2021.765101
63被引13阅读
引用收藏
分享

摘要

Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer with poor prognosis. Surgery, chemotherapy, and radiofrequency ablation are three conventional therapeutic options that will help only a limited percentage of HCC patients. Cancer immunotherapy has achieved dramatic advances in recent years and provides new opportunities to treat HCC. However, HCC has various etiologies and can evade the immune system through multiple mechanisms. With the rapid development of genetic engineering and synthetic biology, a variety of novel immunotherapies have been employed to treat advanced HCC, including immune checkpoint inhibitors, adoptive cell therapy, engineered cytokines, and therapeutic cancer vaccines. In this review, we summarize the current landscape and research progress of different immunotherapy strategies in the treatment of HCC. The challenges and opportunities of this research field are also discussed.

学科与关键词

关键词
immunotherapyhepatocellular carcinomaHCCimmune checkpoint inhibitorsadoptive cell therapyvaccineCAR-TTCR-T
相关
加载中…
  • Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition)
    Yang, Yu; Sun, Juxian; Wu, Mengchao; Lau, Wan Yee; Zheng, Shusen; Wang, Xue-Hao; Chen, Xiaoping; Fan, Jia; Dong, Jiahong; Cai, Jianqiang; Chen, Minshan; Chen, Yongjun; Cheng, Zhangjun; Dai, Chaoliu; Shan, Jianzhen; Du, Cheng-You; Fang, Chihua; Hu, Heping; Ji, Zhili; Jia, Weidong; Li, Gong; Li, Jing; Li, Jiangtao; Liu, Chang; Liu, Fubao; Ma, Yong; Mao, Yilei; Niu, Zuoxing; Shen, Jie; Shi, Jie; Shi, Xuetao; Song, Wenjie; Sun, Hui-Chuan; Tan, Guang; Tao, Ran; Wang, Xiaohu; Wen, Tianfu; Wu, LiqunLiver Cancer, 2022, 11(6): 511-526.被引 9
  • Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity
    Wu, Yaoqiang; Lin, Han; You, Xia; Guo, Taiyan; Sun, Tingting; Xu, Hao*; Fu, Xibo*Frontiers in Oncology, 2022, 12: 764923.被引 2
  • The advanced development of molecular targeted therapy for hepatocellular carcinoma
    Yan, Tao; Yu, Lingxiang; Zhang, Ning; Peng, Caiyun; Su, Guodong; Jing, Yi; Zhang, Linzhi; Wu, Tong; Cheng, Jiamin; Guo, Qian; Shi, Xiaoliang*; Lu, Yinying*Cancer Biology & Medicine, 2022, 19(6): 802-817.被引 17
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Immunology
发表日期
2021-10-04
卷期
第 12 卷
页码
765101
DOI
10.3389/fimmu.2021.765101
语言
ENGLISH
期刊收录
NSL
期刊等级
2区
成果收录
SCIE
资助标注
Natural Science Foundation of Guangdong Province, China [2020A1515010981, 2020A1515110366]; Science and Technology Program of Guangzhou, China [202102080193]; President Foundation of Nanfang Hospital, Southern Medical University [2018C013]; Outstanding Youth Development Scheme of Nanfang Hospital, Southern Medical University [2020J003]

作者

  • L

    Liu, Zhuoyan (第一作者)

    southern med univ

  • L

    Liu, Xuan

    southern med univ

查看全部 8 位作者收起作者
  • L

    Liang, Jiaxin

    southern med univ

  • L

    Liu, Yixin

    southern med univ

  • H

    Hou, Xiaorui

    southern med univ

  • Z

    Zhang, Meichuan

  • L

    Li, Yongyin (通讯)

    southern med univ

  • J

    Jiang, Xiaotao (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417